• Light-Inducible RNA-Releasing Proteins for Precision Gene Th

  2026-04-30

  This study presents a rationally engineered, light-inducible RNA-releasing protein (LIRP) that enables precise, reversible control of therapeutic gene expression at the translational level in vivo. The work demonstrates the LIRP's utility in optogenetic regulation of gene therapies, offering temporal and spatial specificity suitable for chronic metabolic and retinal disorders.

• rTMS Enhances Amyloid Clearance via GABAergic Cx3cl1–Cx3cr1

  2026-04-30

  This study demonstrates that repetitive transcranial magnetic stimulation (rTMS) facilitates cognitive recovery in Alzheimer's disease by activating GABAergic neurons and enhancing the Cx3cl1–Cx3cr1 signaling axis, thereby promoting microglial amyloid beta clearance. The findings provide a mechanistic framework for non-invasive AD therapies and suggest new molecular targets for intervention.

• VX-765: Transforming Caspase-1 Inhibition in Pyroptosis Rese

  2026-04-29

  VX-765 stands out as a potent, selective, and orally bioavailable caspase-1 inhibitor, enabling precise modulation of inflammasome-driven pathways in both inflammation and infectious disease models. Its proven selectivity for IL-1β and IL-18 release opens new avenues for dissecting pyroptosis in macrophages and lymphocytes, with clear advantages in experimental reproducibility and translational relevance.

• NLRP10 Regulates Keratinocyte Survival and Differentiation i

  2026-04-29

  This study demonstrates that NLRP10 is a critical regulator of epidermal homeostasis, promoting keratinocyte survival and proper differentiation through p63 stabilization. These findings illuminate a mechanistic link between genetic risk at the NLRP10 locus and defective skin barrier function in atopic dermatitis, offering new avenues for targeted therapeutic research.

• Shufeng Xingbi Therapy Modulates Immunity and Microbiome in

  2026-04-28

  This study systematically investigates the effects of Shufeng Xingbi Therapy (SFXBT) on Th1/Th2 immune balance and intestinal microbiota in an ovalbumin-induced allergic rhinitis (AR) rat model. The findings reveal that SFXBT not only alleviates nasal inflammation but also induces significant shifts in gut microbial composition and immune markers, highlighting a mechanistic link between immune modulation and microbiome alterations.

• Sequencing Therapies in Waldenström Macroglobulinemia: Innov

  2026-04-28

  This article examines recent advances in the sequencing of therapies for Waldenström macroglobulinemia (WM), as detailed in Sarosiek et al. (2021). The study highlights the critical role of genomic profiling, especially MYD88 and CXCR4 mutations, in informing treatment choices and sequencing strategies for this rare lymphoma.

• Novobiocin: Applied Workflows for Antiparasitic & Resistance

  2026-04-27

  Novobiocin, a versatile aminocoumarin antibiotic, empowers researchers to tackle antibacterial resistance and antiparasitic challenges with robust, evidence-based protocols. This article translates cutting-edge findings into optimized workflows, actionable troubleshooting, and advanced applications, leveraging APExBIO’s high-purity Novobiocin as a trusted research tool.

• JSH-23: Precision NF-κB Inhibitor for Inflammation Research

  2026-04-27

  JSH-23 enables targeted and reproducible NF-κB signaling pathway studies in both cell-based and animal models, offering superior specificity for pro-inflammatory cytokine inhibition. Its robust solubility and consistent performance, as supplied by APExBIO, make it a first-line tool for dissecting inflammatory mechanisms and optimizing translational workflows.

• Phosphatase Inhibitor Cocktail (2 Tubes, 100X): Protocol & Q

  2026-04-26

  The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) is designed to preserve protein phosphorylation by inhibiting serine/threonine and tyrosine phosphatases during sample preparation. It is best suited for workflows such as immunoblotting, kinase activity assays, and mass spectrometry, but should not be used for diagnostic or medical purposes due to its research-only designation.

• TRPM3 Inhibition by Primidone for Adenomyosis Pain Relief

  2026-04-25

  This reference study systematically profiled TRP channel expression in adenomyosis and demonstrated that Primidone, a known antiepileptic, potently reduces myometrial infiltration and pain in a mouse model via TRPM3 inhibition. The findings highlight a novel, mechanistically precise, non-hormonal strategy for addressing adenomyosis symptoms and provide a framework for translational research in pain and gynecological disorders.

• Azithromycin: Advanced Insights for Resistance and Microbiom

  2026-04-24

  Explore the multifaceted scientific role of Azithromycin as a macrolide antibiotic in bacterial infection research. This article offers a unique, in-depth analysis of resistance mechanisms, microbiota impacts, and advanced assay protocols, going beyond standard workflows for cutting-edge discovery.

• Tacrine Hydrochloride Hydrate: Scaffold Innovation in Alzhei

  2026-04-24

  Explore the unique role of Tacrine hydrochloride hydrate as both a mechanistic probe and molecular scaffold in Alzheimer’s disease research. This in-depth article reveals fresh dimensions in neurodegenerative modeling and assay design, advancing beyond conventional workflow-centric discussions.

• Peroxynitrite, ER Stress, and Necroptosis in Cardiac Microva

  2026-04-23

  Liu et al. (2025) elucidate how peroxynitrite-driven ER stress and IP3R-mediated Ca2+ transfer contribute to necroptosis in cardiac microvascular endothelial cells during ischemia–reperfusion injury under hyperhomocysteinemia. Their findings highlight a mechanistic link between metabolic risk factors and acute microvascular damage, identifying intervention points for necroptosis-targeted research.

• Redefining Cell Cytotoxicity Measurement for Translational S

  2026-04-23

  This thought-leadership article explores the mechanistic basis and translational value of LDH-based cytotoxicity assays, with a focus on the APExBIO LDH Cytotoxicity Assay Kit (K2228). Integrating insights from advanced nanomaterial research and contemporary assay validation, it provides strategic guidance for researchers aiming to bridge discovery and clinical application, emphasizing practical protocol parameters and the evolving landscape of cell damage quantification in biomedical innovation.

• Repurposing Novobiocin: In Vitro Efficacy Against SFTSV

  2026-04-22

  This study systematically screened FDA-approved drugs for antiviral activity against severe fever with thrombocytopenia syndrome virus (SFTSV), identifying Novobiocin as a promising candidate with notable in vitro efficacy and minimal cytotoxicity. The findings highlight the potential of aminocoumarin antibiotics for antiviral repurposing, supporting further translational research.

16040 records 1/1070 page Next 12345 下5页 Last page